



eGFR	≥ 90	60–89	45–59	30–44	15–29	< 15	
CKDstage	1	2	3a	3b	4	5	5D
Re-test	12 m	6 m	4 m	3 m	2 m	6 w	



Evidence favours NOAC over VKA for both efficacy and safety
 If vascular calcification or calciphylaxis are a concern, avoid VKAs
 Use appropriate (usually labelled) dose of OAC

^aPatients with CrCl 25–30 ml/min were included in ARISTOTLE.

^bDabigatran is not approved in Europe for the use in patients with severe renal impairment (CrCl <30 mL/min).

^cLimited data are available from subgroups of registries.